Lombristop en es it fr

Lombristop Brand names, Lombristop Analogs

Lombristop Brand Names Mixture

  • No information avaliable

Lombristop Chemical_Formula


Lombristop RX_link


Lombristop fda sheet

Lombristop msds (material safety sheet)

Lombristop Synthesis Reference

No information avaliable

Lombristop Molecular Weight

192.258 g/mol

Lombristop Melting Point

246-266 oC

Lombristop H2O Solubility

1.07E+004 mg/L

Lombristop State


Lombristop LogP


Lombristop Dosage Forms

400 mg and 600 mg tablets for oral administration

Lombristop Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Lombristop Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Lombristop Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Lombristop side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Lombristop Patient Information

Lombristop Organisms Affected

Humans and other mammals